Further to intimation dated July 28, 2023; Gland Pharma has informed that following the ‘Good Manufacturing Practice (GMP) Inspection’ by US FDA at the Company’s VSEZ Sterile Oncology Facility at Visakhapatnam between 20th July, 2023 and 28th July, 2023; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.
The above information is a part of company’s filings submitted to BSE.